Medicure Inc.
http://www.medicure.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medicure Inc.
What’s New, And What’s Coming, In Radiopharmaceuticals
Novartis is the leader when it comes to targeted cancer therapies incorporating radioisotopes. But plenty of companies are trying to break in to this market.
ASCO-GI 2024 – Novartis Tightens Its Grip On The Radiopharmaceutical Space
Lutathera yields a 72% reduction in the risk of progression or death in first-line GEP-NETs trial.
Deal Watch: Lilly Sends European Commercial Rights For Two Migraine Drugs To Organon
Plus deals involving Biocytogen, Neurocrine and Ona, Aeterna Zentaris/Ceapro, Teva/Biolojic Design, Pathos AI/Rain Oncology, Inhibitor Therapeutics/Johns Hopkins and more.
Radiopharmaceutical Leader ITM Gets A Burst Of Energy – And Weighs Up Going Public
ITM is reaping benefits from long-term investment in radiopharmaceuticals manufacturing and is now looking to challenge its customer, Novartis, by bringing its first product to market.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
-
- Mauritius
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice